Skip to main content

Advertisement

SpringerLink
Log in

Defective Skeletal Mineralization in Pediatric CKD

  • Kidney and Bone (SM Moe and IB Salusky, Section Editors)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Although traditional diagnosis and treatment of renal osteodystrophy focused on changes in bone turnover, current data demonstrate that abnormalities in skeletal mineralization are also prevalent in pediatric chronic kidney disease (CKD) and likely contribute to skeletal morbidities that continue to plague this population. It is now clear that alterations in osteocyte biology, manifested by changes in osteocytic protein expression, occur in early CKD before abnormalities in traditional measures of mineral metabolism are apparent and may contribute to defective skeletal mineralization. Current treatment paradigms advocate the use of 1,25(OH)2vitamin D for the control of secondary hyperparathyroidism; however, these agents fail to correct defective skeletal mineralization and may exacerbate already altered osteocyte biology. Further studies are critically needed to identify the initial trigger for abnormalities of skeletal mineralization as well as the potential effects that current therapeutic options may have on osteocyte biology and bone mineralization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; S1–130.

  2. Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:146–52. This is the only pediatric study to evaluate the prevalence of renal osteodystrophy across the spectrum of pre-dialysis CKD.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Groothoff JW, Offringa M, Van Eck-Smit BL, Gruppen MP, Van De Kar NJ, Wolff ED, et al. Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int. 2003;63:266–75.

    Article  PubMed  Google Scholar 

  4. Munns CF, Rauch F, Travers R, Glorieux FH. Three children with lower limb fractures and a mineralization defect: a novel bone fragility disorder? Bone. 2004;35:1023–8.

    Article  PubMed  Google Scholar 

  5. consortium, A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345–8.

    Article  Google Scholar 

  6. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79:112–9. This study revealed that, although PTH and bone turnover decrease during therapy with active vitamin D sterols and phosphate binders, defects in mineralization persist.

    Article  CAS  PubMed  Google Scholar 

  7. Sabbagh Y, Graciolli FG, O’Brien S, Tang W, dos Reis L, Ryan S, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27:1757–72. In conjunction with the 2009 study by Pereira et al, this is one of only 2 studies documenting changes in osteocyte biology that occur early in the course of CKD.

    Article  CAS  PubMed  Google Scholar 

  8. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009;45:1161–8. This was the first study to describe that osteocyte biology is altered in pediatric CKD and to describe that bone FGF23 expression correlates with parameters of skeletal mineralization in the pediatric CKD population.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Jensen PR, Andersen TL, Soe K, Hauge EM, Bollerslev J, Amling M, et al. Premature loss of bone remodeling compartment canopies is associated with deficient bone formation: a study of healthy individuals and patients with Cushing’s syndrome. J Bone Miner Res. 2012;27:770–80.

    Article  PubMed  Google Scholar 

  10. Kupisiewicz K, Boissy P, Abdallah BM, Hansen FD, Erben RG, Savouret JF, et al. Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts. Calcif Tissue Int. 2010;87:437–49.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoSONE. 2008;3:e2942.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Manolagas SC. Cellular and molecular mechanisms of osteoporosis. Aging (Milano). 1998;10:182–90.

    CAS  Google Scholar 

  13. Karsenty G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet. 2008;9:183–96.

    Article  CAS  PubMed  Google Scholar 

  14. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.

    Article  CAS  PubMed  Google Scholar 

  15. Nijweide PJ, Burger EH, Feyen JH. Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol Rev. 1986;66:855–86.

    CAS  PubMed  Google Scholar 

  16. Shalhoub V, Faust J, Boyle WJ, Dunstan CR, Kelley M, Kaufman S, et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem. 1999;72:251–61.

    Article  CAS  PubMed  Google Scholar 

  17. Paiva KB, Granjeiro JM. Bone tissue remodeling and development: Focus on matrix metalloproteinase functions. Arch Biochem Biophys. 2014;561C:74–87.

    Article  Google Scholar 

  18. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res. 1969;3:211–37.

    Article  CAS  PubMed  Google Scholar 

  19. Blair HC, Robinson LJ, Huang CL, Sun L, Friedman PA, Schlesinger PH, et al. Calcium and bone disease. Biofactors. 2011;37:159–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Neuman WFN, Margaret W. (1958). The chemical dynamics of bone mineral, The University of Chicago Press.

  21. Schartum S, Nichols Jr G. Concerning pH gradients between the extracellular compartment and fluids bathing the bone mineral surface and their relation to calcium ion distribution. J Clin Invest. 1962;41:1163–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Green J, Yamaguchi DT, Kleeman CR, Muallem S. Cytosolic pH regulation in osteoblasts. Interaction of Na + and H+ with the extracellular and intracellular faces of the Na+/H+ exchanger. J Gen Physiol. 1988;92:239–61.

    Article  CAS  PubMed  Google Scholar 

  23. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science. 1989;245:855–7.

    Article  CAS  PubMed  Google Scholar 

  24. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet. 2006;78:179–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Lorenz-Depiereux B, Bastepe M, et-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. NatGenet. 2006;38:1248–50.

    Article  CAS  PubMed  Google Scholar 

  26. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int. 1993;43:436–42.

    Article  CAS  PubMed  Google Scholar 

  27. Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med. 1991;324:527–31.

    Article  CAS  PubMed  Google Scholar 

  28. Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:146–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. 1998;54:907–14.

    Article  CAS  PubMed  Google Scholar 

  30. Waller S, Shroff R, Freemont AJ, Rees L. Bone histomorphometry in children prior to commencing renal replacement therapy. Pediatr Nephrol. 2008;23:1523–9.

    Article  PubMed  Google Scholar 

  31. Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, et al. Value of the new bone classification system in pediatric renal osteodystrophy. ClinJAmSocNephrol. 2010;5:1860–6. This is the only study on the ability of different biochemical parameters to predict bone mineralization, as well as turnover, in the pediatric dialysis population.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int. 1998;53:1358–64. This manuscript was the first description of bone histology post kidney transplantation.

    Article  CAS  PubMed  Google Scholar 

  33. Tamminen IS, Valta H, Jalanko H, Salminen S, Mayranpaa MK, Isaksson H, et al. Pediatric solid organ transplantation and osteoporosis: a descriptive study on bone histomorphometric findings. Pediatr Nephrol. 2014;29:1431–40. This manuscript presents the most current data on bone histomorphometric parameters of pediatric transplant recipients.

    Article  PubMed  Google Scholar 

  34. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis. 2005;46:S1–121.

    Article  Google Scholar 

  35. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79:112–9.

    Article  CAS  PubMed  Google Scholar 

  36. Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest. 2012;122:1803–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. De Schutter TM, Behets GJ, Jung S, Neven E, D’Haese PC, Querfeld U. Restoration of bone mineralization by cinacalcet is associated with a significant reduction in calcitriol-induced vascular calcification in uremic rats. Calcif Tissue Int. 2012;91:307–15.

    Article  CAS  PubMed  Google Scholar 

  38. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2008 Annual Report. 2008.

  39. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2006 Annual Report. 2006.

  40. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. 2005.

  41. Bacchetta J, Wesseling-Perry K, Kuizon B, Pereira RC, Gales B, Wang HJ, et al. The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial. Clin J Am Soc Nephrol. 2013;8:824–32. This study is the only one to evaluate bone histomorphometry in pediatric dialysis patients receiving growth hormone.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Sanchez CP, Salusky IB, Kuizon BD, Abdella P, Juppner H, Goodman WG. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int. 1998;54:1879–87.

    Article  CAS  PubMed  Google Scholar 

  43. Nawrot-Wawrzyniak K, Misof BM, Roschger P, Panczyk-Tomaszewska M, Ziolkowska H, Klaushofer K, et al. Changes in bone matrix mineralization after growth hormone treatment in children and adolescents with chronic kidney failure treated by dialysis: a paired biopsy study. Am J Kidney Dis. 2013;61:767–77. This manuscript demonstrated that bone matrix mineralization characteristics change in pediatric transplant recipients treated with growth hormone.

    Article  CAS  PubMed  Google Scholar 

  44. Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, and Salusky IB. Disordered FGF23 and Mineral Metabolism in Children with CKD. Clin J Am Soc Nephrol. 2013.

  45. Gomes SA, dos Reis LM, de Oliveira I, Noronha IL, Jorgetti V, Heilberg IP. Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate [corrected]: an improved method for immunohistochemistry. J Bone Miner Metab. 2008;26:110–3.

    Article  CAS  PubMed  Google Scholar 

  46. Pereira RC, Jüppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009;45:1161–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8.

    Article  CAS  PubMed  Google Scholar 

  48. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, and Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011.

  49. David V, Dai B, Martin A, Huang J, Han X, Quarles LD. Calcium regulates FGF-23 expression in bone. Endocrinology. 2013;154:4469–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008;23:939–48.

    Article  CAS  PubMed  Google Scholar 

  51. Pereira RC, D A, Khouzam N, Bowen R, Freymiller E, Salusky IB, Wesseling-Perry K. Primary osteoblast-like cells from patients with end stage kidney disease reflext gene expression, proliferation and mineralization characteristics ex vivo. Kidney Int. 2014. This manuscript demonstrated that osteoblasts from patients with CKD are phenotypically different than their counterparts from individuals with normal kidney function, suggesting that future studies on the pathophysiology of bone disease will require an understanding of intrinsic alterations to bone cells that occur in the context of CKD.

  52. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, et al. Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. JClinEndocrinolMetab. 2009;94:511–7. This manuscript was the first to identify that FGF23 is a marker of how well bone is mineralized in patients treated with maintenance dialysis.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Lima F, El-Husseini A, Monier-Faugere MC, David V, Mawad H, Quarles D, and Malluche HH. FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis. Clin Nephrol. 2014.

  54. Oliveira RB, Cancela AL, Graciolli FG, dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, and Ortiz A. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant. 2011.

  56. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27:784–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

K Wesseling Perry has received research support unrelated to this manuscript from the NIH, ASN, Genzyme, Genentech, and the Casey-Lee Ball Foundation.

Human and Animal Rights and Informed Consent

All studies by the author involving animal and/or human subjects were performed after approval by the appropriate institutional review boards. When required, written informed consent was obtained from all participants.

Author information

Authors and Affiliations

  1. Pediatric Nephrology, David Geffen School of Medicine at UCLA, A2-383 MDCC, 650 Charles Young Dr, Los Angeles, CA, 93001-1835, USA

    Katherine Wesseling-Perry

Authors
  1. Katherine Wesseling-Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine Wesseling-Perry.

Additional information

This article is part of the Topical Collection on Kidney and Bone

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wesseling-Perry, K. Defective Skeletal Mineralization in Pediatric CKD. Curr Osteoporos Rep 13, 98–105 (2015). https://doi.org/10.1007/s11914-015-0253-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-015-0253-4

Keywords

Search

Navigation